Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | RNASEH1 | O60930 | 3/20 | 0.43 |
| ▸ | PRNP | P04156 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.39 |
| ▸ | TYMP | P19971 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11478282 | 0.85 | RNASEH1 (0.58) | RNASEH1MAPTKMT2A | |
| SCHEMBL11472422 | 0.82 | NPSR1 (0.45) | RNASEH1NPSR1TYMP | |
| SCHEMBL11471579 | 0.81 | RIPK1 (0.44) | RNASEH1LMNAKMT2A | |
| SCHEMBL11485417 | 0.74 | PARP1 (0.52) | CHEK2KMT2A | |
| SCHEMBL17957235 | 0.72 | CA12 (0.41) | CHEK2RNASEH1MAPTLMNAKMT2A | |
| SCHEMBL2816780 | 0.72 | ACR (0.51) | MAPT | |
| SCHEMBL11470135 | 0.72 | GPR52 (0.47) | RNASEH1GPR52 | |
| SCHEMBL11473003 | 0.71 | ADORA3 (0.35) | — | |
| SCHEMBL11253236 | 0.71 | ALDH1A1 (0.34) | MAPTLMNA | |
| SCHEMBL11079269 | 0.70 | FFAR1 (0.44) | CHEK2RNASEH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4218457-A | ANTICANCER ACTIVITY AND IMMUNOSTIMULATING ACTIVITY | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1980-08-19 | — | — | US | disclosed |